IVA Profile
Inventiva S.A. is a clinical-stage biopharmaceutical company dedicated to developing innovative oral small molecule therapies targeting a range of complex diseases. The company focuses on advancing treatments for non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other conditions. Inventiva's lead product candidate, Lanifibranor, is a promising therapeutic agent that has successfully completed Phase IIb clinical trials for the treatment of NASH, a chronic liver disease characterized by fat accumulation and inflammation.
In addition to Lanifibranor, Inventiva is advancing Odiparcil, a treatment for Mucopolysaccharidosis VI (MPS VI), which has also completed Phase IIa clinical trials. MPS VI is a rare genetic disorder that results in the accumulation of glycosaminoglycans, leading to progressive physical and neurological damage. Odiparcil aims to address the unmet medical needs of patients with this challenging condition. The company's portfolio includes several earlier-stage programs across oncology and other therapeutic areas, reflecting its commitment to addressing a broad spectrum of diseases.
Inventiva has formed strategic collaborations with major pharmaceutical companies to enhance its research and development capabilities. Notably, the company has partnered with AbbVie to explore new treatments for autoimmune diseases, leveraging AbbVie's expertise in this field. Additionally, Inventiva is collaborating with Boehringer Ingelheim International GmbH to develop novel therapies for idiopathic pulmonary fibrosis, a severe lung condition characterized by progressive scarring of lung tissue.
Founded in 2011 and headquartered in Daix, France, Inventiva S.A. has rapidly established itself as a leader in the development of cutting-edge biopharmaceuticals. The company’s dedication to advancing novel therapies through robust clinical development programs and strategic alliances positions it at the forefront of innovation in the biopharmaceutical industry. By addressing significant unmet medical needs and pursuing transformative treatments, Inventiva continues to drive progress in the treatment of complex diseases.
|
